A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Pozelimab; Drug: Cemdisiran

• Registration Number: NCT04940364
• Lead Sponsor: Regeneron Pharmaceuticals

Brief Summary

The primary objective of the study is to assess the concentration-time profiles of total pozelimab, total C5, cemdisiran, and cemdisiran metabolite(s) in Japanese adult participants following single doses of intravenous (IV) and subcutaneous (SC) pozelimab and SC cemdisiran when administered on the same day or sequentially 28 days apart.

The secondary objectives of the study are:

* To evaluate the safety and tolerability of pozelimab alone and in combination with cemdisiran in healthy Japanese adult participants

* To assess the pharmacodynamic (PD) profile of pozelimab alone and in combination with cemdisiran in healthy Japanese adult participants

* To assess the immunogenicity of pozelimab and cemdisiran in healthy Japanese adult participants

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-06-17
• Study First Submitted QC: 2021-06-17
• Study First Posted: 2021-06-25
• Study Start: 2021-08-04
• Status Verified: 2022-06
• Primary Completion: 2022-06-22
• Study Completion: 2022-06-22
• Last Update Submitted: 2022-07-01
• Last Update Posted: 2022-07-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Japanese participant must be:

   1. Be Japanese, born in Japan, and have both biologic parents and 4 biologic grandparents who are ethnically Japanese and born in Japan
   2. Have maintained a Japanese lifestyle, with no significant change since leaving Japan, including having access to Japanese food and adhering to a Japanese diet
   3. Living < 10 years outside of Japan

2. Has a Body Mass Index (BMI) between 18 and 30 kg/m2 (inclusive) at screening visit

3. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and ECGs performed at screening and/or prior to administration of initial dose of study drug

4. Is in good health based on laboratory safety testing obtained at the screening visit Note: Participant with suspected or confirmed Gilbert's disease can be enrolled in the study

5. Willing to undergo vaccination against N. meningitidis unless participant has documentation of completed series of vaccinations within the past 2 years of the screening visit

6. Must have two consecutive negative COVID-19 tests at least 48 hours apart and within 7 days prior to study drug administration Note: The test may be the point of care quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) test or approved COVID-19 antigen test at the discretion of the investigator.

Key

Read More

Exclusion Criteria

1. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator as defined in the protocol
2. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study
3. Hospitalization (>24 hour) for any reason within 30 days of the screening visit
4. Has a confirmed positive drug test result at the screening visit and/or prior to enrollment; or a history of alcohol and/or drug abuse within a year prior to the screening visit
5. Is positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) at the screening visit
6. Is positive for hepatitis C antibody and positive for qualitative (i.e., detected) hepatitis C virus (HCV) RNA test at the screening visit
7. Within the previous 2 months of the screening visit has a history of bacterial, protozoal, viral or parasite infection (including COVID-19) and/or persistent chronic or active recurring infection which require treatment with antibiotics, antivirals, or antifungals
8. Known or suspected COVID-19 disease at screening and/or prior to 1st dose administration

NOTE: Other protocol-defined Inclusion and Exclusion criteria apply

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 6	Pozelimab	Pozelimab: Single-dose IV on day 1
Cohort 2	Pozelimab	Pozelimab: Single-dose IV on day 1
Cohort 3	Cemdisiran	Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1
Cohort 4	Pozelimab	Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1
Cohort 1	Pozelimab	Pozelimab: Single-dose SC on day 1
Cohort 4	Cemdisiran	Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1
Cohort 5	Pozelimab	Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1
Cohort 5	Cemdisiran	Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1
Cohort 3	Pozelimab	Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1

Primary Outcome Measures

Name	Time	Method
Concentrations of pozelimab in serum over time	Up to 20 weeks
Concentrations of cemdisiran in plasma over time.	Up to 20 weeks

Secondary Outcome Measures

Name	Time	Method
Concentrations of total C5 in plasma over time	Up to 20 weeks
The incidence and severity of treatment-emergent adverse events (TEAE) in subjects administered pozelimab with/without cemdisiran	Up to 20 weeks
Change from baseline in CH50 over time	Up to 20 weeks
Incidence of treatment-emergent anti-drug antibodies (ADA) to pozelimab	Up to 20 weeks
Incidence of treatment-emergent ADA to cemdisiran	Up to 20 weeks

Trial Locations

Locations (1)

Regeneron Research Site; 🇬🇧 London, United Kingdom